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In this study we assessed whether gliomas could be subdivided into different molec-
ular subtypes by immunohistochemistry (IHC) reminiscent of those first described 
by Verhaak et al. in 2010 (classical, proneural, mesenchymal and neural). We also 
evaluated the prognostic significance of single molecular factors and searched for 
significant correlations between markers. In this study, we included 146 patients 
with glioblastomas (GBMs) and 26 with diffuse astrocytomas (DAs). The glio-
ma samples were tested for PDGFRA, IDH1 R132H, CD44, p53, Ki-67, p21 
and p27 expression. We found that gliomas could be subdivided into molecular 
subtypes by IHC. Fifty per cent of GBMs were of the proneural subtype, 18.5% 
of mesenchymal subtype and 31.5% were not otherwise classified. However, most 
of the DAs (92.3%) belonged to the proneural subtype. No prognostic role was 
found for the molecular subtypes, but predictive roles were noted. Both proneural 
and mesenchymal molecular subtypes showed a benefit from the addition of che-
motherapy and radiotherapy; however, the mesenchymal subtype showed a greater 
response. Interestingly, the mesenchymal subtype did not receive any benefit from 
the addition of radiotherapy compared with palliative management and surgery 
alone. Regarding single molecular markers, only IDH1 R132H was found to have 
a prognostic role for GBMs. There was a trend towards better survival in tumours 
with lower PDGFRA expression (p = 0.066).  In DAs, PDGFRA and Ki-67 ex-
pression had prognostic roles. The following statistically significant correlations 
were found in GBMs: Ki-67/p53, Ki-67/p27 and p53/PDGFRA; in DAs: p53/
PDGFRA, CD44/PDGFRA, and p21/PDGFRA.
Key words: gliomas, immunohistochemistry, molecular subtypes, survival, glio-
blastoma.
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Introduction
Glioblastoma (GBM) represents the most frequent 
and biologically aggressive (grade IV) type of glio-
ma [1]. Glioblastoma has a very poor prognosis in 
spite of aggressive multimodal treatments. Ther-
apy remains mostly palliative due to rapid tumour 
growth and recurrences that occur in almost every 
case. The highly invasive nature of this neoplasm 
prevents the possibility of complete surgical removal 
and contributes to widespread infiltrative disease in 
the surrounding brain parenchyma. Diffuse astrocy-
toma (DA) is a type of low-grade glioma defined as 
a grade II neoplasm by the World Health Organiza-
tion (WHO) [1]. The proliferative potential of DAs 
and their rate of growth is much lower than GBMs. 
DA is also very infiltrative and has a tendency to 
progress towards a high-grade malignancy called an-
aplastic astrocytoma (grade III) and finally secondary 
GBM (grade IV). Low-grade gliomas and secondary 
GBMs are known to bear IDH1 mutations and IDH1 
R132H is the most frequent one. IDH1 mutations 
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are associated with younger patients, as well as 
a much better prognosis in both low-grade and high-
grade gliomas [2]. Extensive research is being direct-
ed towards elucidating the molecular and genetic sig-
natures in gliomas. This can provide more data about 
their pathogenesis and help to improve management 
of gliomas, possibly allowing these tumours to be 
stratified into different prognostic groups. While in-
vestigation of individual gene or protein alterations 
can provide data on potentially important prognostic 
markers, new techniques like DNA microarrays al-
low the measurement of large numbers of genes and 
even provide expression profiles for complete tumour 
genomes simultaneously. At present, several molec-
ular subtypes of GBM have been defined on the ba-
sis of molecular signatures. For example, Verhaak et 
al. described four glioblastoma molecular subtypes 
based on gene expression analysis: classical, proneu-
ral, mesenchymal and neural subtypes. These were 
characterized by different molecular alterations and 
gene expression patterns [3]. In other studies, glio-
blastomas were divided into different subtypes on 
the basis of the activity of various signal transduction 
pathways [4] and protein expression profiles [5, 6, 7]. 
The tumours possessing similar molecular signa-
tures and expression patterns likely share common 
pathogenesis, reflecting similar therapy responses 
and prognoses. Glioma subtyping is possible and of-
fers promise for routine practice, but molecular data 
must be altered to a simpler, cheaper tool for daily 
use. Immunohistochemistry (IHC) is an important 
component of tissue testing in pathology laboratories 
in the emerging molecular era. It is also a good sur-
rogate for the more expensive traditional cytogenetic 
and molecular methods. One of the proteins of inter-
est in many studies is platelet-derived growth factor 
receptor alpha (PDGFRA). The proneural subtype 
of GBM was characterized by PDGFRA amplification 
as well as p53 and IDH1 mutations [3]. The protein 
CD44 is the best known molecule associated with in-
vasion in many tumours, including gliomas [8, 9]. 
Increased expression of CD44 was also found in 
the mesenchymal subtype of GBMs [3]. This indi-
cates that CD44 is worthy of attention as a potential 
determinant of biological aggressiveness and could 
be used in molecular subtyping. Other proteins that 
have been reported to be specific for certain molecular 
glioma subtypes are c-mer proto-oncogene tyrosine 
kinase (MERKT), epidermal growth factor recep-
tor (EGFR), oligodendrocyte transcription factor 2 
(OLIG-2) and assorted others. The aim of our study 
was to investigate expression of PDGFRA, CD44, 
IDH1 R132H, Ki-67, p53, p21 and p27 in GBMs 
and DAs and to identify significant correlations 
of marker expression as well as to compare expres-
sion with clinical parameters such as age and gender. 
In addition, we evaluated whether gliomas could be 
subdivided into several molecular subtypes.
Material and methods
A retrospective study was carried out in compliance 
with laws and regulations considering principles of eth-
ics in accordance with the Declaration of Helsinki. 
In our study, archived formalin-fixed, para-
plast-embedded tissues of 146 GBMs, including 
5 secondary GBMs and 26 DAs were analyzed by im-
munohistochemistry (IHC). Anaplastic astrocytomas 
were excluded from the study because we evaluated 
the two most contrasting grades of diffuse gliomas. 
The cases were identified by an archive search of all 
consecutive patients (2009-2014) who were subject-
ed to neurosurgical treatment by routine indications 
in a single university hospital. The diagnosis and 
grade of the gliomas were verified by 2 pathologists 
in accordance to the 2016 WHO classification of tu-
mours of the CNS [1] as detailed in Table I. Immu-
nohistochemical visualization for IDH1 R132H was 
used for detection of IDH-mutant glioma cases. 
All recurrent tumours and previously treated 
patients, unacceptably small samples including ste-
reotactic biopsies, and damaged material contain-
ing large areas of necrosis or coagulation artefacts 
(> 50% of the sample) were excluded from the study. 
The basic clinical data (e.g. patient's age and gender) 
as well as information about previous treatment or 
tumour recurrences were retrieved from medical re-
cords. The glioma samples were tested for PDGFRA, 
IDH1 R132H, CD44, p53, Ki-67, p21 and p27 ex-
pression by immunohistochemical visualization. For 
IHC, 3-micrometre-thick sections were cut on elec-
trostatic glass slides (Histobond, Marienfeld, Germa-
ny). After deparaffinisation and rehydration, heat-in-
duced antigen retrieval was performed in a microwave 
oven (3 × 5 min) using a basic TEG (pH 9.0) buffer 
(Agilent Dako, Santa Clara, United States of Amer-
ica), followed by blocking of endogenous peroxidase 
(Sigma-Aldrich Ltd., Gillingham, United Kingdom). 
The sections were incubated with primary antibodies 
(see Table II for antibody characteristics and dilution) 
at room temperature. Bound primary antibodies 
were detected by the enzyme-conjugated polymeric 
visualisation system EnVision (Agilent Dako), linked 
with horseradish peroxidase using 3,3’-diaminoben-
zidine (Agilent Dako) as the chromogen. Positive and 
negative quality controls were invariably performed 
and reacted appropriately. Characteristics of the pri-
mary antibodies for immunohistochemistry is shown 
in the Table II.
Expression of markers was evaluated by light mi-
croscopy under magnifications of 40× and 400×, 
using an Eclipse Ci-L (Nikon, Tokyo, Japan) micro-
scope. By intensity, the expression was evaluated 
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Appropriate cellular background: mildly to moderately increased 
cellularity, mild to moderate nuclear atypia, fibrillary architecture, no or 
single1 mitosis
Absence of microvascular proliferation
Absence of necrosis
Molecular parameters:
Presence of IDH1/2 mutations
IDH-mutant
IDH-wildtype





Appropriate cellular background: high cellularity and/ or cellular and 
nuclear atypia and/or brisk mitotic activity




Presence of IDH1/2 mutations
IDH-mutant
IDH-wild type
Louis et al. 2016
1 in a representative tissue material. Stereotactic biopsies excluded by the study criteria
Table II. Characteristics of the primary antibodies for immunohistochemistry
antigen antibOdy clOnality Manufacturer dilutiOn incubatiOn tiMe (Min) pattern
PDGFRA PRAH Polyclonal Abcam 1 : 200 60 Ct, Me
Mutant IDH1 
R132H
MMAH H09 Dianova 1 : 50 60 Ct
CD44 MMAH DF1485 Agilent Dako, 
Santa Clara, USA
1 : 50 60 Me
p53 MMAH DO-7 Agilent Dako 1 : 400 60 Nu
Ki-67 MMAH MIB-1 Agilent Dako 1 : 100 60 Nu
p21 MMAH SX118 Agilent Dako 1 : 25 60 Nu
p27 MMAH SX53G8 Agilent Dako 1 : 50 60 Nu
PDGFRA – platelet-derived growth factor receptor α; MMAH – monoclonal mouse antibody against human antigen; PRAH – polyclonal rabbit antibody against 
human antigens; USA – United States of America; Ct – cytoplasmic; Me – membranous; Nu – nuclear
as negative vs. low vs. moderate vs. high intensity. 
The expression of a marker was considered posi-
tive only if the expression intensity was moderate 
or high. For most markers (Ki-67, p53, p21, p27, 
CD44, PDGFRA) the presence of nuclear, cyto-
plasmic or membranous staining was scored quan-
titatively as the fraction (%) of neoplastic cells. 
The expression of IDH1 R132H mutant protein 
was evaluated only as positive vs. negative. Re-
garding immunohistochemical evaluation, the cas-
es were also classified as positive or negative. For 
a case to be considered positive, the fraction of pos-
itive cells had to reach a certain cut-off value. This 
value was based on the most frequently used lev-
el in other studies published in peer-reviewed in-
ternational journals. The cut-off values for both 
GBMs and DAs were the following: 10% for p53, 
50% for CD44 and PDGFRA, 20% for p21 and 
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70% for p27. For Ki-67, we used cut-off values 
of 25% and 3% for GBMs and DAs respectively. 
The immunohistochemical profiles of p53, IDH1 
R132H, PDGFRA and CD44 expression were used 
to determine the molecular subtype of GBM as pre-
viously described by Verhaak et al., 2010. Based on 
these protein expression signatures, three categories 
of GBMs were distinguished: proneural, mesenchy-
mal and not otherwise classified, designated “Oth-
er”. The proneural subtype was defined by high 
expression of p53 and/or high expression of PDG-
FRA and/or positivity of IDH1 R132H. The mes-
enchymal subtype was defined by high expression 
of CD44 and low expression of proneural markers 
(p53, PDGFRA and IDH1 R132H). All remaining 
cases which did not fit the proneural or mesenchy-
mal subtype categories were classified as “Other”. 
The criteria and algorithm used to distinguish three 
basic proposed subtypes of gliomas is shown in Ta-
ble III and Fig. 1. 
Descriptive statistical analysis was performed 
and included the calculation of a 95% confidence 
interval (CI) by CIA software according to Altman 
et al., 2000. Survival was evaluated using Kaplan- 
Meier analysis and the log-rank test was used to com-
pare the survival curves. To detect significant differ-
ences, a Mann-Whitney U-test was used. For correla-
tion analysis, Spearman’s correlation test was used. 
A value of p < 0.05 was considered to be statistically 
significant.
Results
Characteristics of patients with glioma
The study included 146 patients with GBM and 
26 patients with DAs diagnosed during a period from 
2009-2014 in a single university hospital. GBM was 
diagnosed in 75/146 (51.4%; 95% CI: 43.3-59.5) 
females and in 71/146 males (48.6%; 95% CI: 40.5-
56.7).  The age of the patients ranged from 34-89. 
The mean age ± standard deviation (SD) was 62.0 
±11.2 (95% CI: 60.2-63.8). Surgical resection was 
performed in every studied GBM. In addition, adju-
vant therapy – including radiotherapy and chemo-
therapy with temozolomide – was used. The treat-
ment type data were not available in 11 patients. In 
the remaining 135 GBM patients, standard treat-
ment was given most frequently, consisting of surgery 
followed by adjuvant radiotherapy and chemother-
apy with temozolomide; this accounted for 56/135 
(41.5%; 95% CI: 33.5-49.9) of patients. Surgery was 
followed by radiotherapy alone in 50/135 (37.0%; 
95% CI: 29.3-45.4) cases, but 29/135 (21.4%; 95% 
CI: 15.3-29.1) patients did not receive any adjuvant 
oncological treatment and only surgical resection 
was performed. Patients receiving adjuvant temo-
zolomide and radiotherapy were younger compared 
to those who received adjuvant radiotherapy or who 
were treated with surgical resection alone (one-way 
ANOVA, p < 0.001). The mean age of patients re-
ceiving different types of treatment was 55.0 (95% 
CI: 52.5-57.5) years, 65.9 (95% CI: 62.9-68.7) 
years and 69.0 (95% CI: 65.3-72.7) years. DA was 
diagnosed in 14/26 (53.8%; 95% CI: 34.6-72.7) 
females and 12/26 (46.2%; 95% CI: 27.0-65.4) 
males. The age of patients ranged from 21 to 67 
years. The mean age ± SD was 37.5 ±11.2 (95% CI: 
33.0-42.0). Surgical resection was performed in all 
DAs. In addition, all patients received adjuvant ra-
diotherapy. Clinical characteristics of the enrolled pa-
tients are summarized in the Table IV. 




p53 High Low Low
PDGFRA High Low Low
IDH1 R132H Positive Negative Negative
CD44 Any High Low
PDGFRA – platelet-derived growth factor receptor α; NOS – not otherwise specified






High expression of 
PDGFRA or/and high 
expression of p53  








Glioma, not  
otherwise classified
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Immunohistochemical profile of glioma
GBM demonstrated a marked increase of Ki-67 
proliferation activity compared with DAs: 44.4% 
(95% CI: 41.1-47.6) vs. 6.4% (95% CI: 4.7-8.0). 
Ki-67 proliferation indices ranged from 13-95% in 
GBMs and from 2-15% in DAs. Expression of aber-
rant p53 protein varied significantly in both groups, 
from absence of any immunoreactivity (0%) to strong 
labelling of almost all cells (99%). 
There was no statistically significant difference 
of p53 protein expression by mean fraction of posi-
tive cells between DAs and GBMs (p = 0.416). By 
the selected cut-off, p53 expression was found in 
64.3% (95% CI: 55.6-72.1) of GBMs and 75.0% 
(95% CI: 55.1-88.0) of DAs. Expression of p21 was 
significantly more frequent in GBMs than in DAs: 
21.2% (95% CI: 18.7-23.6) vs. 6.9% (95% CI: 2.4-
11.4). By the selected cut-off, 49.3% (95% CI: 41.3-
57.4) of GBMs and only 15.0% (95% CI: 5.2-36.0) 
of DAs showed expression of p21. Expression of p27 
was common in both GBMs and DAs. However, 
the mean value of p27 expression was lower in GBMs 
than in DAs: 69.7% (95% CI: 65.8-73.7) vs. 86.6% 
(95% CI: 81.6-91.7). Using the cut-off level, high 
p27 protein expression was found in 60.1% (95% CI: 
50.9-68.7) of GBMs and 86.9% (95% CI: 67.8-95.4) 
of DAs. CD44 protein was expressed in a significant-
ly greater fraction of cells in GBMs compared to DAs: 
74.1% (95% CI: 69.6-78.7) vs. 13.5% (95% CI: 
7.7-19.2). Strong expression of CD44 in more than 
50% of neoplastic cells was found in 81.5% (95% CI: 
74.4-86.9) of GBMs; however, only one (3.8%; 95% 
CI: 0.1-19.6) DA reached a high level of CD44 ex-
pression. Significantly increased expression of PDG-
FRA was observed in DAs compared to GBMs 
(p < 0.001). High PDGFRA protein expression was 
observed in 6.2% (95% CI: 5.0-10.6) of GBMs and 
52.6% (95% CI: 30.1-75.0) of DAs, when the cut-
off threshold of 50% was applied. IDH1 R132H 
protein expression was found in 3.4% (95% CI: 
0.5-6.3) of GBMs compared with 76.9% (95% CI: 
60.7-93.1) of DAs. All cases showed intense nuclear 
staining. Among the positive GBM cases, only one 
GBM morphologically showed components of lower 
grade glioma, thus confirming secondary GBM on 
morphological grounds. All IDH1 R132H positive 
GBMs (n = 5) lacked any radiological or clinical evi-
dence of a pre-existing low-grade tumour. The mean 
age of patients with secondary GBMs (IDH1 R132H 
positive) was 50.6 (95% CI: 48.9-52.2) years com-
pared to a mean age of patients with primary 
GBMs (IDH1 R132H negative) of 62.4 (95% CI: 
60.7-64.0) years.
Immunohistochemical characteristics of glioma 
patients are summarized in the Table IV. 
Results of the immunohistochemical visualization 
results showing high and low level of expression of all 
studied markers in gliomas are illustrated in Fig. 2.
Associations and correlations between 
the studied immunohistochemical variables
We found very weak positive correlations be-
tween p53 and the proliferation fraction by Ki-67 
(rs = 0.196; p = 0.027) and PDGFRA (rs = 0.181; 
p = 0.043) in GBMs. Ki-67 also showed a trend 
towards a very weak negative correlation with p27 
(rs = 0.199; p = 0.055).
In DAs, there was a significant moderate, positive 
correlation between PDGFRA and p53 (rs = 0.544; 
p = 0.013). In contrast, the correlation between 
PDGFRA and CD44 was negative, but also of mod-
erate strength (rs = –0.592; p = 0.006). There was 
Table IV. Clinical characteristics of the enrolled patients
paraMeter diffuse astrOcytOMa, grade ii gliOblastOMa, grade iV
Number 26 146
IDH mutant 20 5
IDH wild-type 6 141
Age, years: mean ± SD (range) 37.5 ±11.2 (21-67) 62.0 ±11.2 (34-89)
Overall survival, months: Median (95% CI) Could not be calculated 7.9 (6.8-9.0)
Gender: number; proportion; 95% CI
Females 14; 53.8%; 34.6-72.7 75; 51.4%; 43.3-59.5
Males 12; 46.2%; 27.0-65.4 71; 48.6%; 40.5-56.7
Treatment: number; proportion; 95% CI
Surgery + radiotherapy + temozolamide 56; 41.5%;  33.5-49.9 N/A
Surgery + radiotherapy 50; 37.0%; 29.3-45.4 26; 100%; 89.1-100.0
Surgery only 29; 21.4%; 15.3-29.1 N/A
SD – standard deviation; CI – confidence interval; N/A – not applicable
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Fig. 2. Immunohistochemical detection of Ki-67, p53, CD44, PDGFRA, p21, p27, IDH1 R132H in GBM and DA. 
A staining intensity with high and low expression levels is shown at original magnification of 200× for all immunohis-
tochemical markers
GBM DA







IDH1 R132H IDH1 R132H
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Table V. Immunohistochemical profile of glioma
Variable diffuse astrOcytOMa gliOblastOMa
Ki-67
Mean of Ki-67 expressing cells ±SD (%); 95% CI 6.4% ±3.9; 4.7-8.0 44.4% ±18.5; 41.1-47.6
Median of Ki-67 expressing cells (%); IQR 5.5; 6 41.0; 24
Range of Ki-67 expressing cells (%) 2-15 13-95
No. of high Ki-67 expression status; %; 95% CI  
(cut-off 25% and 3% for GBMs and DAs respectively)
16; 66.7; 46.7-82.0 111; 88.1; 81.2-92.6
p53
Mean of p53 expressing cells ±SD (%); 95% CI 43.4 ±31.7; 30.0-56.8 35.3 ±37.6; 28.7-42.0
Median of p53 expressing cells (%); IQR 52.0; 63 15.0; 71
Range of p53 expressing cells (%) 0-95 0-99
No. of high p52 expression status; %; 95% CI  
(cut-off 10%)
18; 75; 55.1-88 81; 64.3; 55.6-72.1
CD44
Mean of CD44 expressing cells ±SD (%); 95% CI 13.5 ±14.3; 7.7-19.2 74.1 ±27.8; 69.6-78.7
Median of CD44 expressing cells (%); IQR 8.5; 15 86.5; 36
Range of CD44 expressing cells (%) 1-50 5-100
No. of high CD44 expression status; %; 95% CI  
(cut-off 50%)
1; 3.8; 0.1-19.6 119; 81.5; 74.4-86.9
p21
Mean of p21 expressing cells ±SD (%); 95% CI 6.9 ±9.5; 2.4-11.4 21.2 ±15.0; 18.7-23.6
Median of p21 expressing cells (%); IQR 2.5; 7 19.0; 19
Range of p21 expressing cells (%) 0-32 1-68
No. of high p21 expression status; %; 95% CI  
(cut-off 20%)
3; 15.0; 5.2-36.0 72; 49.3; 41.3-57.4
p27
Mean of p27 expressing cells ±SD (%); 95% CI 86.6 ±11.6; 81.6-91.7 69.7 ±21.2; 65.8-73.7
Median of p27 expressing cells (%); IQR 92; 17 74; 31
Range of p27 expressing cells (%) 62-97 2-98
No. of high p27 expression status; %; 95% CI  
(cut-off 70%)
20; 86.9; 67.8-95.4 68; 60.1; 50.9-68.7
PDGFRA
Mean of PDGFRA expressing cells ±SD (%); 95% CI 42.3 ±35.5; 25.7-59.0 7.9 ±17.3; 5.0-10.7
Median of PDGFRA expressing cells (%); IQR 42.0; 68 1.0; 4
Range of PDGFRA expressing cells (%) 1-95 0-90
No. of high PDGFRA expression status; %; 95% CI  
(cut-off 50%)
10; 52.6; 30.1-75.0 9; 6.2; 2.3-10.1
IDH1 R132H
No. of positive IDH1 R132H expression status; %; 95% CI 20; 76.9; 60.7-93.1 5; 3.4; 0.5-6.3
No. of negative IDH1 R132H expression status; %; 95% CI 6; 23.1; 6.9-39.3 141; 96.6; 93.7-99.5
SD – standard deviation; IQR – interquartile range; CI – confidence interval; No. – number; PDGFRA – platelet-derived growth factor receptor α; GBM – glio-
blastoma; DA – diffuse astrocytoma; CD – cluster of differentiation
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a strong negative correlation between PDGFRA and 
p21 in DAs (rs = –0.603; p = 0.008). The full results 
for the correlations between IHC markers are sum-
marized in Table VI where statistically significant 
correlations (p < 0.05) are indicated in bold. 
The Mann-Whitney U test was used to assess 
differences between the IDH1 R132H positive and 
negative groups of GBMs (primary vs. secondary) 
and DAs. There was a trend towards a younger 
age in secondary GBMs (p = 0.060). There was 
also a significantly higher level of p53 expression 
in secondary GBMs (p < 0.001). No significant 
differences were found for IDH1 R132H status 
in DAs.
Survival and prognostic markers of GBM 
patients
The survival data were available for 135 patients, 
all of which have been included in the survival anal-
ysis. At the end of the study, 2/135 (1.5%; 95% CI: 
0-5.2) patients were alive, but 133/135 (98.5%; 95% 
CI: 94.8-99.6) had died during the observation peri-
od. The overall median survival time was 7.9 months 
(95% CI: 6.8-9.0). One-year, two-year and three-year 
survival rates for patients with GBM were 36.3%, 
9.6% and 1.5%, respectively. There was a statisti-
cally significant difference in overall survival (OS) 
regarding the patient’s age (log-rank, p < 0.001); 
median OS times for patients ≤ 65 and > 65 years 
old were 11.7 (95% CI: 8.1-15.3) and 5 (95% CI: 
3.2-6.8) months, respectively. This indicates younger 
age at diagnosis is associated with significantly longer 
survival time in GBM patients. Significant difference 
in median OS was observed in GBM patients by type 
of treatment (log-rank, p < 0.001). Tumours treated 
with the current standard of care – surgery followed 
with radiotherapy and chemotherapy with temozolo-
mide – had a median OS of 12.1 (95% CI: 11.2-13.0) 
months, vs. surgery plus radiotherapy: 7.5 (95% CI: 
5.4-9.6) months, vs. surgery only: 2.9 months (95% 
CI: 1.4-4.4). In GBMs, a statistically significant sur-
vival difference was also found in patients regarding 
IDH1 R132H mutant protein expression (log rank, 
p = 0.040). Patients with secondary GBMs had 
a median OS of 18.3 (95% CI: 18.0-18.5) months vs. 
7.7 (95% CI: 6.3-9.0) months in patients with pri-
mary GBMs. A trend towards a difference in OS was 
found in patients with GBM by PDGFRA expression 
(log rank, p = 0.066). The median OS of patients 
with high PDGFRA expression was 6.4 (95% CI: 
2.8-9.9) months vs. 8.3 (95% CI: 6.4-10.1) months 
in patients with low PDGFRA expression. Regarding 
other immunohistochemical markers, no significant 
survival differences were found.
Survival and prognostic markers of DA patients
The survival data were available for 25 patients, 
which have been included in the survival analysis. 
At the end of the study, 14/25 (56.0%; 95% CI: 
37.0-73.3) patients were alive, but 11/25 (44.0%; 
95% CI: 26.6-62.9) died during the observation 
period. Due to the small study group and small 
Table VI. Correlations between IHC variables in GBMs and DAs by rs and p values






Ki-67/p53 0.196 0.027 0.339 0.106
Ki-67/CD44 –0.162 0.070 –0.130 0.544
Ki-67/PDGFRA 0.098 0.274 –0.002 0.992
Ki-67/p21 –0.060 0.503 0.146 0.551
Ki-67/p27 –0.199 0.055 0.276 0.226
p53/CD44 –0.073 0.414 –0.382 0.066
p53/PDGFRA 0.181 0.043 0.544 0.013
p53/p21 0.019 0.829 –0.20 0.282
p53/p27 0.037 0.725 0.149 0.518
CD44/PDGFRA –0.141 0.090 –0.592 0.006
CD44/p21 0.037 0.659 0.170 0.474
CD44/p27 –0.144 0.128 0.302 0.162
PDGFRA/p21 –0.152 0.067 –0.603 0.008
PDGFRA/p27 –0.056 0.555 0.149 0.555
p21/p27 0.119 0.211 –0.290 0.229
CD – cluster of differentiation; PDGFRA – platelet derived growth factor receptor α; rs – Spearman’s rank correlation coefficient; GBM – glioblastoma; DA – diffuse 
astrocytoma; IHC – immunohistochemistry
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Fig. 3. Kaplan-Meier survival curves by glioblastoma (GBM) subtype and treatment type. In general, there are no differ-
ences in overall survival between molecular subtypes of GBMs, however, Kaplan-Meier analysis has showed that survival 
is different by distinct treatment type. Thus, in proneural and mesenchymal GBMs addition of temozolomide improved 
survival, however, mesenchymal subtype appears to be resistant to addition of radiotherapy. A) Survival by GBM molec-
ular subtype. B) Survival by proneural subtype and treatment type. C) Survival by mesenchymal subtype and treatment 
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number of death cases, statistical calculations are 
insufficient and overall median survival time could 
not be calculated. Within the first year following 
surgical operation, all patients were alive (25/25). 
Two years after the initial operation, 3/25 (12%; 
95% CI: 4.2-29.9) patients had died, but 22/25 
(88%; 95% CI: 70.0-95.8) were alive. Three 
years after the initial operation, 5/25 (20%; 95% 
CI: 8.8-39.1) patients had died, but 20/25 (80%; 
95% CI: 60.9-91.1) were alive. In DAs, statistical-
ly significant differences in survival were found in 
patients regarding PDGFRA expression (log rank, 
p = 0.017). Interestingly, there were no significant 
survival differences regarding Ki-67 expression 
using the selected cut-off of 3%. However, when 
we tried a higher cut-off value of 5.5%, which was 
based on the median Ki-67 expression rate in DAs, 
a statistically significant difference in survival was 
found (log rank, p = 0.037).
Molecular subtypes of gliomas
The majority of GBM cases were of the proneu-
ral subtype: 73/146 (50.0%; 95% CI: 42.0-58.0) 
cases, followed by “Other” (not otherwise classi-
fied) for 46/146 (31.5%; 95% CI: 24.5-39.4) pa-
tients, and the mesenchymal subtype in 27/146 
(18.5%; 95% CI: 13.0-25.6) patients. There were 
no associations between the molecular subtypes 
of the GBMs and any of the clinical or other im-
munohistochemical parameters (Ki-67, p21, p27). 
There were no differences in OS between molecu-
lar subtypes of GBMs (log rank, p = 0.424) (Fig. 
3A). Furthermore, the level response to therapy 
was evaluated on survival in the different GBM 
subtypes. As shown in Fig. 3B, in the proneural 
subtype there was a trend suggesting the addi-
tion of temozolomide improved OS compared with 
radiotherapy alone (p = 0.061). However, a vi-
sual trend towards a difference between the Ka-
plan-Maier curves was more readily apparent. 
Radiotherapy also improved OS in the proneural 
subtype compared with surgery alone (p = 0.008). 
In the mesenchymal subtype, the addition of temo-
zolomide significantly improved OS compared with 
radiotherapy alone (p = 0.002). However, addition 
of radiotherapy did not improve OS of the patients 
with the mesenchymal subtype compared with sur-
gery alone (p = 0.857) (Fig. 3C). Thus, addition 
of radiotherapy did not provide any benefit com-
pared to surgery alone in patients with the mesen-
chymal subtype. In “Other” GBMs (not otherwise 
classified), there was only a statistically significant 
difference in OS between the GBMs threated with 
adjuvant chemotherapy and radiotherapy com-
pared with solely surgically treated (p = 0.031). 
There were no statistically significant differences 
between the other groups: temozolomide + radio-
therapy vs. radiotherapy alone (p = 0.319) and ra-
diotherapy vs. surgery only (p = 0.080) (Fig. 3D).
Most of the DAs, 24/26 (92.3%; 95% CI: 75.8-
97.9) patients, belong to the proneural subtype; 
the remaining 2/26 (7.6%; 95% CI: 2.1-24.1%) DAs 
were not otherwise classified (“Other”). 
Discussion
Diffuse gliomas do not rank among the tumours 
with the highest incidence; nevertheless, they rank 
among the most aggressive human malignancies with 
limited treatment options. Thus, better understand-
ing of specific signaling pathways and molecular al-
terations determining the biological features of glio-
mas – e.g. invasion, proliferation, resistance to current 
therapy – can provide hope for improving specific 
management, specifically, development of personal-
ized therapy as well as targeted management. 
In the last decade, several studies have been per-
formed to identify subtypes of gliomas based on mo-
lecular and proteomic signatures [2, 3, 7, 10, 11]. For 
example, Verhaak et al. described four glioblastoma 
molecular subtypes based on gene expression analy-
sis: classical, proneural, mesenchymal and neural [3]. 
Existence of proneural and mesenchymal GBM mo-
lecular subtypes was also suggested by other large-
scale molecular study carried out by Phillips et 
al. [12]. The latest 2016 WHO classification of CNS 
tumours is a huge step forward as it significantly 
improves classification of gliomas by incorporating 
molecular data in a glioma diagnostics. However, 
discussions about previously described proneural and 
mesenchymal subtypes are still ongoing [13, 14, 15]. 
From all these subtypes, especially, mesenchymal 
subtype is one of the most consistent subtypes de-
scribed in the literature [14, 15, 16]. Identification 
of mesenchymal signature in glioma tissues brings 
certain clinical interest because it is associated with 
worse prognosis [3, 17]. 
However, molecular techniques are time consum-
ing and expensive, and thus some molecular data 
must be replaced with cheaper and simpler tools such 
as IHC. To date, several authors have shown suc-
cessful attempts of molecular glioma subtyping by 
the means of IHC [5, 6, 18, 19]. 
In the current study, we used IHC to assess the ex-
pression of some of the proteins that have been re-
ported to be significant in subtyping (PDGFRA, 
IDH1 R132H, p53, CD44) or determining basic 
biological features of malignant tumours such as in-
vasion, proliferation and cell cycle regulation (Ki-67, 
p21, p27). 
In this study, no survival differences were found 
between molecular GBM subtypes. With regard to 
clinical outcome, the mesenchymal subtype is de-
scribed as a subtype with an unfavourable prognosis; 
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this is in contrast to the better prognosis by which 
the proneural subtype is characterized [3, 12, 14, 20]. 
However, we found a predictive role for these mo-
lecular subtypes: a response to adjuvant therapy 
was found to be different for proneural vs. mesen-
chymal subtypes. Thus, both molecular subtypes 
showed a benefit from addition of chemotherapy to 
radiotherapy; however, in the mesenchymal subtype, 
the beneficial effect of adjuvant chemotherapy was 
more prominent compared to radiotherapy alone. In-
terestingly, the mesenchymal subtype did not show 
any beneficial effect from the addition of radiother-
apy compared with palliative management and sur-
gery alone (p = 0.857), but in the proneural subtype 
addition of radiotherapy was beneficial (p = 0.008). 
This finding may indicate a  possible radioresistance 
of the mesenchymal subtype of GBM. In contrast, 
Verhaak et al. reported that more intensive treatment 
significantly reduced mortality in the mesenchymal 
subtype of GBM. However, in the study by Ver-
haak et al. the effect of radiotherapy alone was not 
reported; all patients with less intensive and more 
intensive therapy received combined concurrent or 
non-concurrent chemo-radiotherapy or chemothera-
py of varying intensities [3]. Supporting our finding, 
Brown et al. reported radioresistancy in the mesen-
chymal subtype while preserving chemo-sensitivity 
of the mesenchymal subtype [21]. Several authors 
have also reported that the mesenchymal subtype is 
associated with a stem cell phenotype, enriched with 
the presumed stem cell marker CD44 [22]. Howev-
er, glioma mesenchymal stem cells are characterized 
by extensive radioresistency [23, 24, 25], which may 
explain the failure of radiotherapeutic effectiveness in 
the mesenchymal subtype of GBMs in this study. 
Regarding DAs, the significance of subtyping 
in low-grade gliomas should be further evaluated. 
The low-grade gliomas are enriched primarily with 
markers for the proneural subtype [26, 27]. In addi-
tion, high frequency of IDH1 mutations in low-grade 
gliomas account for the majority of the proneural 
subtype [28]. Because CD44 expression was very 
low in DAs, a mesenchymal designation might only 
be of importance in GBMs but not in DAs. Presence 
of the IDH gene mutations is one of the known prog-
nostic factors for a relatively favourable prognosis in 
patients affected with high-grade gliomas [2, 29, 30, 
31]. IDH gene mutation identify secondary GBMs 
with much better prognosis [32]. Median overall sur-
vival rates of mutated and non-mutated IDH1 pa-
tients with GBMs are 3.8 and 1.1 years, respective-
ly [2]. Presence of IDH mutation in glioma so greatly 
determines prognosis of the patient that testing for 
IDH mutation now is also included in diagnostic 
criteria’s of gliomas in the 2016 WHO classification 
of tumours of the CNS [1]. Screening for the IDH 
gene mutations is also possible by the means of IHC. 
Antibodies specific for the products of IDH1 R132H 
mutation may be of sufficient value of screening tool 
to replace more formal mutational analysis [33, 34]. 
In this study, patients with secondary GBMs 
(IDH-mutant) had significantly better progno-
ses than those with primary GBMs (IDH-wild-
type): median OS was 18.3 months vs. 7.7 months 
(p = 0.040). Regarding DAs, patients with IDH1 
R132H negative and IDH1 R132H positive tumours 
did not show any statistically significant survival 
differences (p = 0.336) in this study. Also, an asso-
ciation between IDH1 and p53 was also found in 
GBMs (p = 0.001); the finding that these two ab-
normalities frequently coexist is supported by other 
authors [32]. Interestingly, another single molecular 
marker, PDGFRA, showed a trend (p = 0.066) to-
ward better prognosis in GBMs and was significant-
ly (p = 0.017) associated with a better prognosis in 
DAs. The clinical impact of PDGFRA in gliomas 
has been debated in several studies but there is no 
consensus yet. Increased expression of PDGFRA has 
been reported in proneural GBMs that have better 
prognosis, as described by several researchers [3, 12]. 
However, other authors reported no association be-
tween PDGFRA expression and prognosis in glioma 
patients [35]. In the current study, Ki-67 prolifera-
tion fraction was found to be a useful indicator for 
a worse prognosis in DAs; however, prognostic sig-
nificance was found by using a higher cut-off value 
of 5.5% instead of the 3% cut-off chosen initially. 
Although Ki-67 proliferation fraction is not included 
in the latest WHO classification system, assessment 
of Ki-67 may be useful for identification of increased 
proliferative activity in DAs with otherwise typical 
low-grade gliomas. Such cases of DAs might need 
more careful follow-up and have a worse progno-
sis [36]. In this study, Ki-67 proliferation fraction 
correlated with p53 protein expression (rs = 0.196; 
p = 0.027), indicating oncogenic properties of p53 
upregulate proliferation in neoplastic cells. Also, 
another cell cycle inhibitor, p27, had a trend to-
wards an inverse correlation with Ki-67. Thus, loss 
of p27 and upregulation of p53 may be indicators 
for more proliferative features in GBMs. Regarding 
p53 correlation with PDGFRA in both GBMs and 
DAs, it seems to be a reasonable association, be-
cause both TP53 and PDGFRA gene mutations are 
more frequently associated with the proneural sub-
type of GBMs as described by Verhaak et al. [3]. In 
DAs, CD44 expression has a negative correlation 
with PDGFRA (rs = –0.592; p = 0.006). In addi-
tion, Conray et al. showed that high scores of CD44 
were rarely found in gliomas with high PDGFRA ex-
pression [37]. Cautiously considering that PDGFRA 
pathway activation in different classifications has 
been considered to be a marker for proneural/proneu-
ral-like glioblastoma but CD44 expression is point-
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ing towards the mesenchymal subtype, a negative as-
sociation seems to be more reasonable. Interestingly, 
PDGFRA also had a negative correlation with p21 
(rs = –0.603; p = 0.008) in DAs.
In addition to mesenchymal and proneural GBM 
subtypes, Verhaak et al. described classical and neu-
ral subtypes. The neural subtype is relatively poorly 
characterised and defined by the expression of genes 
such as NELF and GABR, which are mainly expressed 
in normal neurons. However, the classical subtype is 
characterised by EGFR gene amplification and fre-
quent expression of the EGFRvIII protein. Thus, it 
would be necessary in future studies to include other 
IHC markers such as EGFR, NELF and GABR, as 
well as other mesenchymal markers, such as YKL-40, 
MERTK and CD44. We believe GBMs which re-
mained unclassified in this study, called “Other” 
could be classified by using additional markers.
In conclusion, our results indicate an existence 
of two mutually exclusive molecular signatures in 
gliomas reminiscent to those proneural and mesen-
chymal subtypes. In our study, assessment of the ex-
pression of only four proteins (p53, CD44, PDGFRA 
and IDH1) by IHC was able to define these subtypes 
of gliomas. This assessment is cheaper and less time 
consuming than other molecular approaches and is 
easily applicable in routine practice. Because of sim-
ple reproducibility, our findings have huge practical 
interest and the panel of these four markers can be 
used for simple molecular subtyping which is crucial 
for prediction of treatment response in glioma pa-
tients. In addition, detection of IDH1 R132H mu-
tation by IHC is simple and cheap prognostic test for 
glioma patients.
The authors declare no conflict of interest. 
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